

Review of: "[Review Article] Nanocarriers for Protein and Peptide Drug Delivery"

Muhammad Naeem¹

¹ National University of Medical Sciences

Potential competing interests: No potential competing interests to declare.

Nanocarriers for Protein and Peptide Drug Delivery

Qeios, CC-BY 4.0 · Article, November 14, 2023

Article Type: [Review Article]

This review article is precisely focused on the development of structure-based nanocarriers for protein and peptide drug delivery. However, following minor changes can make this manuscript more understandable for researchers in the area.

- 1) Abstract: Include a brief mention of "other scientific sources" in the materials and methods section of the abstract to provide transparency about the diverse range of references used for the study.
- 2) Introduction: Replace "vaccination" with "vaccines" for clarity in the introduction. In the sentence about disadvantages, rephrase to avoid repetition: "Nanoparticles present certain drawbacks, including skin barriers, local allergies, and permeability."
- 3) Potential Nanocarrier Approaches: In the section discussing potential nanocarrier approaches, ensure that there is no unnecessary repetition, especially regarding nanoemulsion.
- 4) Liposome Section: When introducing the abbreviation "GIT" in the Liposome section, explicitly state its full form on its first mention for clarity.
- 5) Polymeric Nanoparticles: Address any repetition in the passage related to Polymeric Nanoparticles to improve the flow and clarity of the content.
- 6) Solid Liquid Nanoparticles (SLN): When introducing the abbreviation "SLN," ensure that its full meaning is specified on its first mention to enhance reader understanding.
- 7) Conclusion: Consider ending the conclusion with a concise and impactful statement that reinforces the significance of nanocarriers in advancing protein and peptide drug delivery